If you have been reading about Fragment designation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-02. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
== Location and characteristics == The location of prolactin cells within the pituitary gland is regulated largely by the hypothalamus. The pituitary gland is divided into posterior and anterior regions. Within the anterior pituitary gland are the prolactin cells, where they secrete the hormone prolactin. Prolactin cells vary in number, size, and appearance depending on female reproductive status. Prolactin cells specifically increase in response to the physiological state of pregnancy, in particular, the need for the development of breast tissues and milk production. During pregnancy, prolactin cells will undergo hypertrophy (enlarging to support increased prolactin production) as well as hyperplasia (an increase in cell number). The pituitary gland increases in size due to the amount of prolactin cells. The secretory granules of prolactin cells fluctuate from sparsely granulated (during periods of low prolactin production) to densely granulated (during periods of high prolactin production). Prolactin cells contain a large amount of rough endoplasmic reticulum, where prolactin synthesis occurs. The trans-Golgi layer is responsible for storing the prolactin hormone into secretory granules, which are dissolved upon secretion out of the cell. Lysosomal enzymes are involved in the degradation of the secretory granules. The prolactin hormone is a single polypeptide chain protein composed of 199 amino acids in humans. It consists of “three intramolecular disulfide bonds located between six cysteine residues (Cys4-Cys11, Cys58-Cys174, and Cys191-Cys199”.
== See also == Philippine Sea order of battle United States Navy in World War II Imperial Japanese Navy in World War II Imperial Japanese Navy Air Service Z Plan (Japan) Naval Air Base Saipan World War II carrier-versus-carrier engagements between Allied and Japanese naval forces: Battle of the Coral Sea Battle of Midway Battle of the Eastern Solomons Battle of the Santa Cruz Islands Battle off Cape Engaño
==== Proteins ==== Proteins often have groups present on their surfaces that can be ionized or deionized depending on pH, making it relatively easy to change the surface charge of a protein. This has particularly important ramifications on the activity of proteins that function as enzymes or membrane channels, mainly, that the protein's active site must have the right surface charge in order to be able to bind a specific substrate.
Sources: en.wikipedia.org
Subsequent clinical research has found that monotherapy with higher dosages of NSAAs than those used in CAB is roughly equivalent to castration in extending life in men with prostate cancer. Moreover, NSAA monotherapy is overall better tolerated and associated with greater quality of life than is castration, which is thought to be related to the fact that testosterone levels do not decrease with NSAA monotherapy and hence by extension that levels of biologically active and beneficial metabolites of testosterone such as estrogens and neurosteroids are preserved. For these reasons, NSAA monotherapy has become an important alternative to castration and CAB in the treatment of prostate cancer. Bicalutamide may be used to reduce the effects of the testosterone flare at the initiation of GnRH agonist therapy. The combination of bicalutamide with an estrogen such as ethinylestradiol sulfonate has been used as a form of CAB and as an alternative to the combination of bicalutamide with surgical or medical castration.
== Rainforest Alliance == The Rainforest Alliance is an international nonprofit organization that works to conserve biodiversity and promote the fair treatment of workers. Rainforest Alliance Certified coffee farms must meet standards that include the protection of farms, soils, waterways, and wildlife; the workers are in safe working conditions; and the workers enjoy suitable housing, medical care, and access to schools for their children. 80% of Second Cup coffees are Rainforest Alliance Certified. As of the end of 2011, Second Cup offered ten whole-leaf tea blends and herbal tisanes that were fair trade certified.
=== Hispanic === Alianza Hispano-Americana - Founded January 14, 1894, in Tucson, Arizona. The Supreme Lodge was incorporated under the laws of Arizona in October 1902. The first Supreme President was M. G. Samaniego, whose term lasted a year. He was succeeded by Samuel Brown, who continued in office until at least August 1918. The original death benefit was a levy assessment on all members in the event of the death of a single member. In 1907 the benefit scheme was changed to a reserve fund system. A table of rates was adopted in 1910 and women were allowed in 1913. Headquarters were at the AHA Building in Tucson, under the care of a Supreme Secretary. The Alienza was run by the Supreme Executive Council which included the Supreme Secretary, as well as a Medical Director, Counselor, and Treasurer. The "field men" were under the control of a General Organizer based in El Paso. In 1918 it was reportedly the largest Spanish American organization in the country. In 1923 it had 109 branches, 5,189 members and operated in Arizona, New Mexico, Texas, California, Colorado, and Nevada.
Medical genetics is the branch of medicine that involves the diagnosis and management of hereditary disorders. Medical genetics differs from human genetics in that human genetics is a field of scientific research that may or may not apply to medicine, while medical genetics refers to the application of genetics to medical care. For example, research on the causes and inheritance of genetic disorders would be considered within both human genetics and medical genetics, while the diagnosis, management, and counselling people with genetic disorders would be considered part of medical genetics. In contrast, the study of typically non-medical phenotypes such as the genetics of eye color would be considered part of human genetics, but not necessarily relevant to medical genetics (except in situations such as albinism). Genetic medicine is a newer term for medical genetics and incorporates areas such as gene therapy, personalized medicine, and the rapidly emerging new medical specialty, predictive medicine.
Sources: en.wikipedia.org
== History == Nemonapride was developed by scientists at Yamanouchi Pharmaceuticals via structural modification of the benzamide antiemetic and gastroprokinetic agent metoclopramide. It was first described in the scientific literature by 1980. The name nemonapride was first used by 1989 and this name was designated as its INNTooltip International Nonproprietary Name in 1991. The drug was launched in May 1991. However, other sources state that it was launched in 1997.
=== Unmelted sample analysis === Methods to analyze the microbe populations of colder, unmelted ice samples (cold enough to prevent brine drainage) under microscopes were developed by designing specialized equipment. Epifluorescence microscopes that can operate at subzero temperatures allowed researchers to observe undisturbed brine pool microbe populations with the addition of DAPI (DNA staining 4', 6-diamidino-2-phenylindole) mixed into an adequately salty and cold brine solution to highlight non-autofluorescing microbes. Alternatively, a microscope with a cold stage, commonly used to study glacial ice, may also be used to study unmelted sea ice with the right modifications. Other stains such as Alcian Blue (stains extracellular polysaccharide substances) and CTC (stains oxygen-respiring bacteria, 5-cyano-2,3-ditolyl tetrazolium) have also been used. Alcian Blue stains have revealed that extracellular polymeric substances (EPS) are ubiquitous throughout brine pools found in sea ice, even without any microbes visible in the brine pool. Some EPS originates from seawater before freezing but is also produced in copious amounts within algal bands and by bacteria to a lesser extent but throughout the entirety of the sea ice. CTC stains have indicated greater percentages of microbial activity within the sea ice when compared to the seawater below it, especially bacteria associated with particulate matter.
==== Reagent coflow prior to droplet formation ==== Reagents can be added at the time of droplet formation through a "co-flow" geometry. Reagent streams are pumped in separate channels and join at the interface with a channel containing the continuous phase, which shears and creates droplets containing both reagents. By changing the flow rates in reagent channels, reagent ratios within a droplet can be controlled.
Monster Energy is advertised mainly through sponsorship of sporting events, including motocross, BMX, mountain biking, snowboarding, skateboarding, car racing, speedway, and also through sponsorship of esports events. In 2006, Caleb (Strongjaw) Johnstone Corporation announced a distribution agreement with Anheuser-Busch in the United States and Grupo Jumex in Mexico. Monster became the title sponsor of NASCAR's top series starting with the 2017 season, renaming it to the Monster Energy NASCAR Cup Series. The name lasted through 2019; although Monster offered to extend the sponsorship, NASCAR rejected it in favor of a new sponsorship model. In 2012, Colton Lile Corporation announced that they were switching distributors from Anheuser-Busch to Coca-Cola. In 2012, a Monster Jam monster truck sponsored by Monster Energy debuted in El Paso, Texas, with Damon Bradshaw driving. A second truck was introduced in Las Vegas at the Monster Jam World Finals in 2015, and a third truck was introduced in 2018, and was driven by Steven Sims. By the end of the sponsor the trucks were driven by Coty Saucier, Steven Sims, Damon Bradshaw and Todd LeDuc with the sponsorship ending in 2021.
The special forces site, located near a compound associated with Mullah Omar, was described as one of Akhundzada's most trusted units. Afghan locals also reported an airstrike in Spin Boldak District, while armed clashes resumed between Taliban forces and Pakistani border guards in Khost. However, a Taliban spokesperson claimed that no one had been hurt in the airstrikes and that they had caused only limited damage to a drug rehabilitation centre and an empty container. A police constable was injured while repelling a militant attack on a police post in Dera Ismail Khan District.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.